Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
In this issue:
Drug safety advice
-
Recombinant human erythropoietins: new prescribing advice
-
Rosiglitazone and pioglitazone: cardiovascular safety
-
Dosulepin: measures to reduce risk of fatal overdose
-
ACE inhibitors and angiotensin II receptor antagonists: not for use in pregnancy
-
Short-acting β agonists: myocardial ischaemia
Yellow Card scheme update
-
electronic reporting
Hot topics
-
Varenicline: possible effects on driving, and psychiatric illness*
-
NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks
Stop Press
-
Aprotinin: suspension of Marketing Authorisations
-
Lumiracoxib: suspension of Marketing Authorisations
-
Strontium ranelate: risk of severe allergic reactions
-
Talc for pleurodesis: risk of adverse events
-
Recent letters to healthcare professionals
Other information from the MHRA
-
New sections on the MHRA website
*Please note that this article quotes incorrect usage figures for varenicline. Up to the end of November 2007, about 240 000 people in the UK had used varenicline.
Drug Safety Update: Volume 1, Issue 5, December 2007 
